RSV in Babies: The Signs, the New Antibody Shot and When to Go to Hospital

The sound is what parents remember. Not the cough, but the little grunt at the end of each breath, and the way the skin between the ribs tucks in with every inhale. A four-month-old who was merely snuffly on Tuesday is suddenly working for air on Thursday night, and nobody in the house sleeps.

Searches for rsv in babies spike every autumn, but as of October 2025 the curve is steeper than usual, and the reason is good news rather than bad. For the 2025–26 season, US infants have two long-acting antibody injections to choose from, after a second product was approved in June 2025, and a maternal vaccine given in pregnancy has completed its second full winter. Pediatric offices are fielding the same three questions on repeat: is the shot a vaccine, who qualifies, and how do I know when a cold has become something worse?

This piece answers all three with the evidence graded honestly, and with the hospital red flags spelled out in plain language, because that is the part you need at 2 a.m.

What changed recently: a second antibody for the 2025–26 season

Three dated events explain the current attention. In July 2023 the US Food and Drug Administration approved nirsevimab (brand name Beyfortus), a long-acting monoclonal antibody designed to protect infants through an entire RSV season; the following month the Centers for Disease Control and Prevention recommended it for all babies entering their first season. A monoclonal antibody is a laboratory-made copy of one specific immune protein, in this case one that locks onto the virus before it can enter airway cells.

Also in August 2023, a maternal RSV vaccine (brand name Abrysvo) was approved for use late in pregnancy, so that the mother’s antibodies cross the placenta and arrive with the baby. That gave families two routes to the same destination: antibodies in the infant’s blood before the virus shows up.

Then, in June 2025, a second long-acting infant antibody, clesrovimab (brand name Enflonsia), was approved, and the CDC’s advisory committee added it to the infant schedule for the 2025–26 season. CDC pages now list both products side by side for babies under eight months entering their first season.

Why the surge in searches rather than quiet relief? Partly supply. The first nirsevimab season in 2023–24 saw shortages, and parents who were turned away then are checking early now. Partly results: CDC surveillance published in 2024 reported roughly 90 percent effectiveness against RSV hospitalization in the first real-world season, a figure that travels fast on parenting forums. And partly confusion, because a product given by injection in the pediatrician’s office is easy to mistake for a vaccine, which it is not. The sections that follow sort out what each of these facts means for a specific baby, with eligibility stated exactly as CDC guidance frames it and every decision left where it belongs, with the prescribing clinician.

What is RSV, and why does it hit babies hardest?

Respiratory syncytial virus is one of the most ordinary pathogens on earth. Nearly every child has met it by their second birthday, and most adults catch it repeatedly without ever learning its name, because in a healthy adult it behaves like a mild cold. The word syncytial comes from the way infected cells fuse into clumps, called syncytia, which is one reason the lining of a small airway swells and sheds so readily.

Babies are a different story for reasons of plumbing, not weakness. An infant’s bronchioles, the narrowest branches of the airway tree beyond the main bronchi, are roughly the diameter of a pencil lead. When RSV inflames that lining and fills it with mucus and dead cells, the airway radius shrinks, and resistance to airflow rises dramatically with even a small narrowing. The same amount of swelling that barely troubles a ten-year-old can halve the effective airway of a two-month-old. Bronchiolitis, the medical term for this inflammation of the small airways, is the condition most parents actually mean when they say their baby has RSV.

Two more factors stack the deck. Infants breathe almost entirely through the nose, so a blocked nose directly interferes with feeding and sleep. And babies under about three months have immature control of breathing, which is why RSV in the very young can show up as pauses in breathing, called apnea, rather than the cough and wheeze seen in older infants.

None of this means the average baby will be hospitalized. It means the margin for error is narrower, so the watching matters more. According to the CDC, RSV is the leading cause of hospitalization among US infants, which says as much about how common the virus is as about how severe any single case will be.

What are the signs of RSV in babies? Rsv symptoms in babies by age

The first two days rarely look alarming. Expect a runny nose, a modest fever, less interest in feeding and some fussiness, which is to say an ordinary cold. The pattern that distinguishes RSV tends to appear on day three to five, when the infection reaches the lower airways.

• Faster breathing. A resting infant normally takes about 30 to 50 breaths a minute; sustained rates above 60 are a warning sign.
• Wheezing or a whistling sound on breathing out, and sometimes crackles that a parent can feel through the chest.
• Retractions. The skin pulls in beneath the ribs, between the ribs or at the base of the neck with each breath, a visible sign of extra effort.
• Nasal flaring and grunting, which are the body’s attempts to keep the small airways open.
• A wet, persistent cough that can linger well after the baby otherwise feels better.
• Feeding less than usual, because a baby cannot suck, swallow and breathe quickly at the same time.

In babies under about two months, and especially those born prematurely, the picture can be subtler and more dangerous. The CDC specifically notes that very young infants may show only irritability, reduced activity, poor feeding or apnea, with no obvious cough at all. A newborn who stops breathing for longer than about 10 seconds, or whose lips or tongue look blue or gray, needs emergency care immediately.

Fever is often lower than parents expect and is not a reliable gauge of severity. The honest marker of how a baby is coping is work of breathing combined with feeding: a baby who is breathing fast but still taking most feeds is usually managing; one who is breathing fast and refusing feeds is not. Mayo Clinic and NHS guidance both make the same point, which is why clinicians ask about wet diapers before they ask about temperature.

Is RSV in babies serious? The honest numbers

Both reassuring and sobering facts are true at once, and parents deserve both. Most babies with RSV have a cold, maybe a rough week, and recover fully at home. The CDC estimates that two to three of every 100 infants under six months are hospitalized with RSV, which means 97 to 98 are not.

Multiply that by the size of a birth cohort, though, and the aggregate is large. CDC surveillance puts RSV hospitalizations at roughly 58,000 to 80,000 children under five each year in the United States, with the greatest share in the first months of life, and an estimated 100 to 300 deaths annually in that age group. Most hospitalized infants need oxygen or help with feeding for a few days and go home; a small fraction need intensive care.

Risk is not evenly spread. The CDC lists several groups at higher risk of severe disease: babies born prematurely, infants under six months, those with chronic lung disease of prematurity, certain heart conditions present from birth, weakened immune systems or neuromuscular conditions that impair swallowing or clearing mucus. Yet one of the more surprising findings from US surveillance is that the majority of infants hospitalized for RSV were previously healthy and born at term, simply because healthy term babies are the largest group.

Timing also matters. A baby born in September meets the virus at two or three months old, at the peak of the season, whereas a baby born in April meets it closer to a year, with larger airways and a more experienced immune system. That calendar logic is the entire basis for the current prevention strategy, which focuses on the first season of life.

So is RSV in babies serious? Usually not for any individual child, often enough across the population that pediatrics has reorganized around it, and occasionally dangerous enough that the red flags in this article should be read, not skimmed.

Is RSV contagious? How the virus actually spreads

Yes, and efficiently. RSV travels in respiratory droplets when an infected person coughs or sneezes, and on hands and surfaces afterward. The CDC notes that the virus can survive for several hours on hard surfaces such as crib rails, countertops and toys, and for shorter periods on soft surfaces like tissues and hands. A toddler who wipes a nose and then grabs the baby’s pacifier has completed the chain.

The incubation period, meaning the gap between exposure and first symptoms, is typically four to six days. People are usually contagious for three to eight days, often starting a day or two before symptoms appear, which is why asking visitors whether they feel ill is only partly protective. Some infants, and people with weakened immune systems, can keep shedding the virus for as long as four weeks even after they seem well.

Where does a two-month-old catch it? Overwhelmingly from the people who love them. Older siblings in daycare or school are the single most common source, followed by parents and visiting relatives with what they assume is a trivial cold. Adults rarely feel sick enough to stay away, and that mismatch between how mild RSV feels in a grown-up and how serious it can be in an infant is the core public health problem.

Practical steps that the evidence supports are unglamorous. Handwashing with soap for 20 seconds before handling the baby; keeping anyone with cold symptoms, including coughing toddlers, from kissing the baby’s face; cleaning high-touch surfaces during the season; and limiting crowded indoor gatherings for the youngest infants in peak months. Masks on symptomatic adults around a newborn are reasonable. None of these is a guarantee, which is exactly why the antibody options discussed later exist. Reducing exposure buys time; antibodies cover the gaps that time cannot.

How long does RSV last in babies, and which days are worst?

A typical course runs one to two weeks, with a recognizable arc. Days one and two are cold-like. Days three to five are the trough, when lower airway symptoms peak and most hospital admissions happen. From about day six onward, breathing effort usually eases, feeds improve and the baby starts to sleep for longer stretches again, even while the cough persists.

That cough can be stubborn. NHS guidance on bronchiolitis notes that a cough can continue for up to four weeks after the rest of the illness has settled, and a lingering noisy chest in week three does not by itself mean the infection has returned or become bacterial. Mucus is still clearing, and infant airways are slow to calm down.

Fever, when present, usually settles within the first few days. If a fever returns after it had resolved, or a baby who was improving slides backward, that pattern deserves a clinician’s assessment because it can signal a secondary ear infection or, less commonly, pneumonia.

Appetite often lags behind breathing. A baby who takes small volumes frequently for several days is doing exactly the right thing, and smaller, more frequent feeds are what hospital teams use too. What matters is hydration, tracked by wet diapers, rather than hitting usual volumes.

Two more timing facts help parents calibrate expectations. Infection does not grant lasting immunity; children can catch RSV again in the same season or the next, though repeat illnesses are usually milder. And a proportion of infants who had severe bronchiolitis go on to have recurrent wheezing in early childhood. Observational data link the two, but it remains unclear whether RSV causes the later wheeze or whether infants predisposed to wheeze are also the ones who get sicker with RSV. That is the honest state of the science, and it is not a reason for alarm after one bout.

How do you treat a baby with RSV at home?

There is no antiviral medicine that treats RSV in an otherwise healthy infant, and antibiotics do nothing against a virus. What works is supportive care, meaning keeping the baby comfortable, hydrated and breathing as easily as possible while the immune system does the work.

Start with the nose. Because infants are obligate nose-breathers, clearing it before feeds and sleep makes a disproportionate difference. A few drops of saline followed by gentle suction with a bulb syringe or a nasal aspirator is the single most useful thing a parent can do. Resist suctioning constantly; a few times a day, before feeds, is plenty, and over-suctioning irritates the lining.

Feed little and often. Short, frequent feeds, whether breast or bottle, are easier for a baby who tires quickly. Count wet diapers rather than ounces. A cool-mist humidifier in the room may ease congestion for some babies, although trial evidence for it is thin; keep it clean to avoid mold.

Hold the baby upright on your chest while awake; it helps the airways drain. For sleep, always place the baby flat on the back on a firm surface, as safe-sleep guidance requires. Do not prop the crib mattress, and do not use pillows or positioners.

Fever management should follow your pediatrician’s specific advice for the baby’s age and weight, and no over-the-counter cough or cold product should be given to an infant. Honey is unsafe under one year because of the risk of infant botulism. Vapor rubs, essential oils and steam from a hot shower have no supporting evidence and can irritate airways or cause burns.

Keep the air clean: no smoke, including secondhand smoke on clothing. Then watch. The most important treatment at home is attentive observation, and knowing the point at which home care is no longer enough, which the next two sections cover.

What happens if a baby with RSV goes to hospital?

Knowing the sequence in advance takes some of the fear out of it. In the emergency department a nurse will measure oxygen saturation with a small sensor wrapped around the baby’s foot, count the breathing rate and look at the chest for retractions. Many departments also perform a quick nasal swab to confirm RSV, which does not change treatment much but helps with infection control and lets staff reassure parents about what to expect.

Admission decisions rest on three questions. Is the oxygen level persistently low? Can the baby feed enough to stay hydrated? Is the baby showing apnea or exhaustion? A yes to any one is generally enough.

Treatment on the ward is still supportive, just with better tools. Oxygen is delivered through soft nasal prongs. Babies working hard may be moved to high-flow nasal cannula, which pushes warmed, humidified air at higher rates to reduce the effort of each breath. Those who cannot feed are given fluids by a thin tube passed through the nose into the stomach, or through an intravenous line. Nurses suction the nose before feeds, exactly as parents do at home.

What is deliberately not routine deserves saying out loud. Inhaled bronchodilators, the asthma rescue medicines, have not shown benefit in bronchiolitis trials and are not recommended for routine use. Steroids, likewise, do not shorten the illness. Antibiotics are reserved for a confirmed bacterial complication such as an ear infection. Chest X-rays are avoided unless the picture is unusual, because they do not change management and expose the baby to radiation. Parents who ask why the team is doing so little are often hearing the answer that modern evidence has pared away treatments that did not help.

Most admissions last two to four days. A small minority of infants need intensive care for breathing support, and even then the great majority recover fully.

When to see a doctor: red flags that mean do not wait

Treat this section as the one to screenshot. Any medicine, immunization or symptom decision for your baby belongs to the treating clinician, but these signs tell you when to involve one, and how fast.

Call emergency services or go to the emergency department immediately if your baby:

• Has pauses in breathing, or lips, tongue or face that look blue, gray or dusky.
• Is breathing very fast, grunting with each breath, or has deep retractions that pull the chest in sharply.
• Is unusually floppy, hard to wake, or does not respond to you the way they normally would.
• Is under three months old and has a fever of 100.4°F (38°C) or higher, regardless of other symptoms.

Contact your pediatrician the same day, or an urgent care service if the office is closed, if your baby:

• Is taking less than about half of normal feeds, or has gone 12 hours without a wet diaper.
• Has a breathing rate consistently above 60 breaths a minute at rest, or visible retractions even when calm.
• Has a fever that returns after settling, or any fever lasting more than three days.
• Was improving and then gets worse, or is still clearly unwell after a week.
• Was born prematurely, has a heart or lung condition, or a weakened immune system, and develops any cold symptoms at all.

Trust the pattern, not the thermometer. A baby with a low-grade fever who is breathing hard and refusing feeds is sicker than one with a higher fever who is cross but drinking. If something about your baby’s breathing frightens you and you cannot name why, that instinct is a legitimate reason to be seen; experienced clinicians take parental concern seriously because it is often right.

The same rule applies after an antibody injection or any immunization. Mild tenderness at the site or a brief rash are the expected, minor effects. Swelling of the face or lips, hives spreading over the body, or difficulty breathing within hours of the injection are rare but need emergency care.

The new RSV antibody shot for babies: what it is and how it works

Here is the distinction that trips up almost everyone. A vaccine teaches the body to manufacture its own antibodies, a process that takes weeks and relies on an immune system mature enough to respond. A monoclonal antibody skips the lesson and hands the baby finished antibodies directly. Protection begins almost immediately and then slowly fades as the antibody is cleared, which is why the infant products are designed to last through a single RSV season rather than for life.

Nirsevimab and clesrovimab both target a protein on the surface of RSV called the F protein, which the virus uses to fuse with and enter cells. Both antibodies are engineered so that they are cleared from the body far more slowly than a natural antibody, extending coverage to months. The CDC describes them as passive immunization: the protection is real, but it is borrowed rather than learned, and the infant will still mount their own immune response to RSV when eventually exposed, usually as a milder illness.

An older antibody, palivizumab, works on the same principle but is cleared quickly, so it is reserved for certain high-risk infants and is largely being replaced by the long-acting products in US practice.

The maternal vaccine takes the other route. Given late in pregnancy, it prompts the mother to make high levels of RSV antibodies, which cross the placenta in the final weeks and protect the newborn for roughly the first six months. Because the transfer depends on those last weeks, CDC guidance specifies a window in pregnancy, and a baby born too soon after the mother’s vaccination may still be offered the infant antibody.

Side effects for the infant antibodies in trials were mostly injection-site reactions and rash, at rates similar to placebo for serious events. Any history of a severe allergic reaction is something to tell the clinician beforehand. None of this is a reason to self-arrange anything; the pediatrician assesses eligibility and gives the injection.

Who is eligible? CDC guidance, side by side

Eligibility is set by the CDC and applied by the clinician, and it hinges on three variables: the baby’s age, whether the mother received the maternal vaccine, and the calendar. In most of the continental United States, infant antibodies are offered from October through March; in Alaska and some tropical and southern regions the window differs because RSV circulates on a different schedule.

Option	What it is	Who CDC guidance covers	Evidence base
Maternal vaccine (Abrysvo)	Vaccine given to the pregnant parent; antibodies cross the placenta	Pregnant people at 32–36 weeks, during September through January in most of the US	Large randomized trial plus two seasons of surveillance
Nirsevimab (Beyfortus)	Long-acting monoclonal antibody given to the infant	Infants under 8 months entering or born during their first season, if not protected by maternal vaccine; children 8–19 months at increased risk entering a second season	Two large randomized trials; strong real-world data since 2023
Clesrovimab (Enflonsia)	Long-acting monoclonal antibody given to the infant	Infants under 8 months entering or born during their first season, if not protected by maternal vaccine	One large randomized trial; first US season in 2025–26
Palivizumab	Older, shorter-acting monoclonal antibody	Selected high-risk infants, per the clinician, when long-acting products are unavailable or not advised	Older randomized trials; declining use

A few nuances the table cannot hold. CDC guidance says that most babies whose mother was vaccinated at least two weeks before delivery do not need the infant antibody, though a clinician may still recommend it for high-risk infants or where the maternal response may be reduced. Babies born outside the window, for example in June, are offered the antibody at the start of the following October. Second-season eligibility for nirsevimab is limited to children with specific risk conditions listed by the CDC, such as chronic lung disease of prematurity, significant heart disease or severe immune compromise.

Whether a given baby qualifies, which product is used and when it is given are decisions for the pediatrician, who has the full history in front of them.

What the evidence actually says, and how strong it is

Evidence comes in grades, and RSV prevention sits in an unusually strong position for something so new.

Nirsevimab: high-quality evidence. The MELODY trial, a randomized, placebo-controlled study of healthy late-preterm and term infants published in the New England Journal of Medicine in 2022, found about a 75 percent reduction in medically attended RSV lower respiratory infection over 150 days. HARMONIE, a second large randomized trial across three European countries published in 2023, reported an 83 percent reduction in RSV hospitalization. Randomized trials are the top of the evidence hierarchy because chance assigns who gets the product, which strips out the biases of comparing families who sought it against those who did not.

Real-world performance: strong observational data. After the first US season, CDC surveillance reported roughly 90 percent effectiveness against RSV hospitalization among infants who received nirsevimab. Observational findings rank a step below trials because the two groups may differ in ways that are hard to measure, but when observational results match the trials this closely, confidence rises.

Maternal vaccine: high-quality evidence, with caveats. The phase 3 trial reported roughly 82 percent efficacy against severe RSV lower respiratory illness in the first 90 days of life, declining to around 69 percent by 180 days. A related vaccine from another manufacturer was halted in development over a signal for preterm birth; the approved product did not show a statistically significant increase, but the CDC’s timing window was chosen partly with that question in mind. That is uncertainty handled responsibly, not hidden.

Clesrovimab: one randomized trial. Approval rested on a large placebo-controlled study showing a meaningful reduction in medically attended RSV illness. It is reasonable to expect similar performance to nirsevimab, but real-world data will arrive only after this season.

Supportive care: guideline consensus built on trials. Multiple randomized trials have failed to show benefit from bronchodilators or steroids in bronchiolitis, which is why guidelines advise against routine use. Evidence for humidifiers and nebulized saline is mixed and low certainty. Nasal suction and small frequent feeds rest on physiology and expert consensus rather than large trials, which is fine for low-risk measures.

Common myths about RSV in babies, corrected

Viral posts travel faster than evidence, so here are the claims pediatric teams hear most, and what the data say.

Myth: the antibody shot is a vaccine that gives the baby RSV. It contains no virus, live or inactivated, and cannot cause infection. It is a purified antibody protein, and the baby’s own immune system is not asked to do anything with it.

Myth: RSV is just a cold, so there is nothing to worry about. In adults, yes. In infants under six months, two to three in 100 are hospitalized, and the CDC identifies it as the leading cause of infant hospitalization in the United States. Both statements are true; the age of the patient is the difference.

Myth: only premature babies get seriously ill. Prematurity raises risk, but most infants hospitalized with RSV were born at term and were previously healthy. That is precisely why the recommendation covers all infants in their first season rather than only high-risk ones.

Myth: antibiotics will clear it up faster. Antibiotics act on bacteria and have no effect on RSV. They are prescribed only if a bacterial complication such as an ear infection develops.

Myth: breastfeeding alone prevents RSV. Breast milk provides some antibodies and is associated with milder illness in observational studies, but it does not prevent infection, and breastfed infants are still hospitalized with RSV. It complements, rather than replaces, immunization.

Myth: a strong-smelling vapor rub or essential oil will open the airways. No trial supports this in infants, and some ingredients are irritants or unsafe for babies.

Myth: the antibody was rushed and untested. Nirsevimab was studied in two large randomized trials involving thousands of infants before approval and has since been given to millions of babies across several countries with ongoing safety monitoring. New products always warrant scrutiny; this one has had it.

Myth: once a baby has had RSV, they are immune. Reinfection is common, usually milder.

Protecting a newborn from RSV at home, daycare and family gatherings

Immunization carries most of the weight, but households still shape how much virus a baby meets, and in what dose. Think of it as lowering the number of coin flips rather than rigging any single one.

Siblings are the usual carriers. A preschooler cannot reliably keep a distance from a newborn, nor should they have to, but a few habits help: hands washed on arrival home and before touching the baby, kisses directed at the top of the head rather than the face, and a firm rule that a child with a runny nose does not share pacifiers, cups or toys with the infant. Keeping a sick toddler home from daycare for the first day or two of a cold protects the baby and the classroom.

Visitors are the second channel. Grandparents and friends with a scratchy throat often assume they are not sick enough to cancel. During the peak months, a polite request to postpone until symptoms have passed is reasonable, and so is asking adult visitors to wash hands before holding the baby. Older adults are themselves a group for whom RSV can be serious, and CDC guidance now includes RSV vaccination for adults aged 75 and over and for those 60 to 74 at increased risk; whether that applies to a particular grandparent is a question for their own clinician.

Environment matters too. Smoke exposure, including residue on clothing, is one of the stronger modifiable risk factors for severe bronchiolitis. Crowded, poorly ventilated indoor spaces concentrate droplets, so the first winter is a good one for smaller gatherings. Clean toys and surfaces that pass between a sick sibling and the baby.

Daycare for the infant is a legitimate trade-off rather than a mistake. Infants in group care do catch more respiratory viruses in the first year; they also catch them later, with bigger airways. If a baby attends daycare during their first season, that is a strong argument, not a weak one, for discussing the antibody with the pediatrician before the season begins.

After RSV: recovery, lingering cough and what the next season looks like

Recovery rarely ends on the day a baby feels better. The cough can last three to four weeks, feeds may stay slightly reduced for a week or so, and sleep often takes a fortnight to normalize. None of that is a cause for concern on its own. What warrants a call is a baby who stops improving, develops a new fever or shows the breathing signs listed in the red-flag section.

A proportion of infants who had severe bronchiolitis go on to have episodes of wheezing with later colds, sometimes for a few years. Observational studies have documented the association for decades; what remains unresolved is direction. Severe RSV may injure developing airways, or the babies most likely to wheeze later may also be the ones most likely to get badly ill with RSV in the first place, with both outcomes reflecting the same underlying airway sensitivity. Early data from antibody and vaccine programs will eventually help answer this, because preventing severe RSV in a randomized group lets researchers see whether later wheeze falls too. For now, a parent should expect the possibility of a wheezy winter or two, mention it to the pediatrician, and not assume asthma has been diagnosed.

A second RSV infection is likely at some point and is usually much milder, because the child’s airways are larger and the immune system now has some memory. Second-season antibody protection is reserved for children with specific risk conditions, as the eligibility table notes.

What matters most, in this writer’s reading of the evidence, is simple. The first six months of life are the window of real danger, the tools to narrow that window are now well tested, and the signs that a cold has become more than a cold are learnable in an afternoon. Learn them before the season starts, raise the antibody question with the pediatrician early, and then treat RSV for what it is: a common virus that deserves respect, not dread.

Frequently asked questions

What are the first signs of RSV in babies?

The first signs are usually a runny nose, mild fever and reduced appetite, indistinguishable from a cold. The signs that point toward RSV bronchiolitis come later, typically on day three to five: breathing faster than 60 times a minute, wheezing, skin pulling in between the ribs, nasal flaring and feeding less. In babies under two months the only signs may be irritability, sleepiness or pauses in breathing.

Is RSV in babies serious?

For most infants, no; they have a cold or a rough week and recover at home. For a minority it is serious: two to three of every 100 babies under six months are hospitalized, mainly for oxygen or feeding support, and RSV is the leading cause of infant hospitalization in the United States. Prematurity, heart or lung conditions and age under six months raise the risk, but most hospitalized babies were healthy and born at term.

Is RSV a very contagious virus?

Yes. RSV spreads through droplets from coughs and sneezes and survives for hours on hard surfaces and shorter periods on hands. People are contagious for three to eight days, often beginning before symptoms appear, and some infants shed the virus for up to four weeks. Older siblings and adults with mild colds are the usual source of infection for a newborn, which is why handwashing and keeping sick visitors away matter.

How do you treat a baby with RSV?

Treatment is supportive, because no antiviral treats RSV in otherwise healthy infants and antibiotics do not work on viruses. At home that means saline drops and gentle nasal suction before feeds, small frequent feeds, upright holding while awake, a smoke-free environment and careful watching of breathing and wet diapers. In hospital, babies receive oxygen, sometimes high-flow air, and tube or intravenous fluids if they cannot feed. Any fever medicine should follow your pediatrician’s advice.

How long does RSV last in babies?

Most RSV illnesses last one to two weeks. The first two days are cold-like, days three to five are usually the worst for breathing and feeding, and improvement generally begins around day six. The cough can linger for up to four weeks after a baby otherwise seems well. A fever that returns after settling, or a baby who was improving and then worsens, should be assessed by a clinician.

Is the RSV antibody shot for babies a vaccine?

No. Nirsevimab and clesrovimab are monoclonal antibodies, laboratory-made immune proteins given directly to the infant so protection starts right away and lasts through a season. A vaccine instead trains the body to make its own antibodies over weeks. The antibody products contain no virus and cannot cause RSV. The maternal product given in pregnancy is a true vaccine; it works by passing the mother’s antibodies to the baby before birth.

Which babies are eligible for the RSV antibody according to the CDC?

CDC guidance covers infants under eight months who are born during or entering their first RSV season and were not protected by a maternal vaccine given at least two weeks before delivery. Nirsevimab is also recommended for children aged 8 to 19 months with specific risk conditions entering a second season. In most of the US the season window runs October through March. Your pediatrician confirms eligibility and timing for your baby.

How well does the RSV antibody work in real life?

Very well, by current evidence. Randomized trials found nirsevimab reduced medically attended RSV lower respiratory illness by about 75 percent and hospitalization by about 83 percent. CDC surveillance after the first US season reported roughly 90 percent effectiveness against RSV hospitalization. Clesrovimab was approved on the strength of one large randomized trial and is in its first US season, so real-world data for it are still being gathered.

Can a baby still get RSV after the antibody shot or maternal vaccine?

Yes, though it is much less likely to be severe. Neither option blocks every infection; both are designed to prevent the lower airway illness that leads to hospital. A protected baby who catches RSV typically has a milder cold-like illness. The same red flags apply regardless of immunization status: fast breathing, retractions, blue lips, pauses in breathing or poor feeding always warrant prompt medical assessment.

When should I take my baby to the hospital with RSV?

Go immediately if your baby has pauses in breathing, blue or gray lips or face, deep retractions with grunting, is unusually floppy or hard to wake, or is under three months with a fever of 100.4°F or higher. Call your pediatrician the same day for breathing faster than 60 breaths a minute at rest, taking under half of usual feeds, 12 hours without a wet diaper, or any worsening after initial improvement.

References

• CDC: RSV in Infants and Young Children
• CDC: RSV Immunization Guidance for Infants and Young Children
• NHS: Bronchiolitis
• MedlinePlus: Respiratory Syncytial Virus Infections

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.